DIG
LCTX icon

Dauntless Investment Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Dauntless Investment Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131 Buy
+100
New +$138 ﹤0.01% 69
2025
Q4 		– Sell
-1,614,100
Closed -$2.73M – 79
2025
Q3 		$2.73M Buy
1,614,100
+408,170
+34% +$483K 1.71% 15
2025
Q2 		$731K Buy
+1,205,930
New +$715K 1.27% 13

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Dauntless Investment Group's LCTX Position: Q2 2026 in Review

Dauntless Investment Group opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 100 shares worth $131. The stake represents ﹤0.01% of the portfolio and ranks #69 among its holdings. This is a return to the name: Dauntless Investment Group previously reported a position in LCTX as recently as Q3 2025.

Dauntless Investment Group first reported a position in LCTX in Q2 2025 and has held it in 3 quarters since. The position peaked at $2.73M in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Dauntless Investment Group held 100 shares of Lineage Cell Therapeutics worth $131 as of Q2 2026.
  • Lineage Cell Therapeutics was a new Dauntless Investment Group position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Dauntless Investment Group's portfolio in Q2 2026, its #69 holding.
  • Dauntless Investment Group first reported a position in Lineage Cell Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Dauntless Investment Group's Lineage Cell Therapeutics position peaked at $2.73M in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Dauntless Investment Group's 13F filing for Q2 2026, filed 13 Aug 2026.